Table 1 Fasting PCSK9 and lipid levels pre- and post-fibrate treatment
From: Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
Baseline | Treatment | % Change | |
|---|---|---|---|
PCSK9 (μg/mL) | 6.04 ± 1.10 | 6.90 ± 1.38* | 17.01 ± 29.5 |
Total cholesterol | 6.22 ± 0.73 | 5.50 ± 0.88** | -11.3 ± 11.6 |
Triglycerides | 3.27 ± 0.59 | 1.85 ± 0.80*** | -43.6 ± 22.8 |
HDL cholesterol | 0.86 ± 0.13 | 1.00 ± 0.21** | 15.7 ± 18.4 |
LDL cholesterol | 3.85 ± 0.65 | 3.65 ± 0.71 | -4.22 ± 17.6 |
TC/HDLC Ratio | 7.35 ± 1.22 | 5.79 ± 1.68*** | -22.0 ± 13.5 |